double-skinned crabsVietnamese crab exporter
Advertisement
Advertisement
TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Commercial success of drugs in China does not guarantee clinical success in overseas markets, according to analysts. Photo: Shutterstock
Stocks

Chinese biotech faces reality check as ArriVent drug failure sinks stock in US

US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial.

Biomedicine: Industry Trends

Hong Kong needs new funding model to attract global drug makers: AstraZeneca

videocam
China technology

Chinese biopharma’s global expansion

Mainland China

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation.

AstraZeneca has moved to advance Chinese biotech firm Akeso’s flagship cancer drug. Photo: Reuters
Biomedicine: Industry Trends

How Chinese biotech is graduating from licensing deals to broader partnerships

InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say.

Hong Kong stock market

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.

videocam
Advertisement
Advertisement
Advertisement
Alibaba

Alibaba open-sources AI model that can detect cancer and nearly 150 conditions

Tested on nearly 40,000 real-world exams, the model outperformed most radiologists, according to a new study published in Science.

Alibaba’s Damo Academy was established in 2017, with recent focus areas including AI tools for cancer detection. Photo: Getty Images
Biomedicine: Policy

Biomedicine powerhouse: China targets quarter of global first-in-class drugs

New five-year plan aims to turn the sector into a pillar industry by 2030, driven by breakthroughs in technologies across critical fields.

Biomedicine: Industry Trends

ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boom

As AI’s role in drug design advances rapidly, Chinese start-ups are ramping up fundraising efforts.

videocam
Biomedicine: Industry Trends

GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

4
GSK has agreed a deal worth up to US$750 million to license a T-cell engager from a Chinese biotechnology firm. Photo: Reuters
Greater Bay Area

Data from Greater Bay Area residents to help improve healthcare policy: GSK

Executive says pharmaceutical company is investing in shared data infrastructure.

GSK’s general manager for Hong Kong and Macau, Nicholas Teo, at the Hong Kong International Biotechnology Conference and Exhibition on Thursday. Photo: Jonathan Wong
IPO

Hong Kong watchdog investigates Cloudbreak Pharma for ‘rigged’ IPO

Regulator cites ‘serious concerns’ about ‘artificial impression of demand’ in US-based company’s US$78 million listing in 2025.

Greater Bay Area

Hong Kong targets biomedicine powerhouse status in debut 5-year plan

Tied to the national strategy, the city’s first five-year blueprint doubles down on Greater Bay Area medical tech and healthcare cooperation.

Technology

As China embraces AI, few US pharmaceutical execs bet on it for innovation

Survey finds drug companies planned to scale AI or had already done so, but few anticipated a ‘wholesale revolution’ from the tech.

videocam
A study of 50 US pharmaceutical company executives found all firms had either fully or partially scaled AI or were planning to. Photo: Shutterstock Images
China’s private sector

China needs monkeys: lab animal shortage could hinder biotech growth

As fundraising and out-licensing deals in China grow, so does demand for monkeys and other primates for testing.

The expansion of China’s biotechnology industry is driving up demand for primates. Photo: Shutterstock
IPO

More Chinese developers of brain-computer interfaces move towards IPOs

Arfysica and Neuracle aim for Star Market listings amid what a Morgan Stanley analyst calls the ‘early stage of a multi-year IPO upcycle’.

videocam
Banking & finance

Why Asian investors are pouring capital into brain tech and surgical robots

Family offices and venture investors across Hong Kong and the wider region are reshaping portfolios to capture long-term biotech growth.

Advertisement
Advertisement
Advertisement
Banking & finance

US surgical robotics firm targets Hong Kong listing to tap mainland China market

Noah Medical expects to file application as early as next year, joining surge of tech listings tapping city’s international fundraising pool.

videocam
Noah Medical has begun preparations for a Hong Kong listing. Photo: Handout
Artificial intelligence

Biomedicine | China thinks big on brain-computer interfaces

Launch of commercial BCI implantation, ahead of US, offers hope to millions with brain or spinal injuries as plans are made for the technology’s wider use.

Hong Kong stock market

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.

Hong Kong stock market

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.

videocam
7
Chinese biotechnology firms are working on more than 100 cancer vaccine programmes, according to analysts. Photo: Shutterstock
Wuxi Biologics

WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds

Higher gross margins, surging projects and continued demand from North American markets help power the drug developer’s strong first-half performance.

Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province, China. Photo: Shutterstock
Medicine

Overseas licensing has helped fuel China’s biotech profits. Will it last?

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.

videocam
Hong Kong economy

Chinese tech, pharma firms eye Hong Kong as springboard for global expansion

Industry leaders highlight city’s international reach and expertise as state-owned drug maker considers Northern Metropolis project investment.

Science

Chinese stem cell therapy restores heart function in 90% of trial patients

Study finds patients injected with iPSC-derived heart muscle cells outperform control group on cardiac function tests after bypass surgery.

videocam
12
Patients with severe heart failure may experience shortness of breath after walking just a few steps, the inability to lie flat and sleep at night, and frequent hospital visits. Photo: Shutterstock
Biomedicine: Industry Trends

Patience needed before human gene therapy trials, Stanford expert says

Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.

videocam
Karoly Nikolich, pictured at the Hong Kong Convention and Exhibition Centre on August 8. Photo: Edmond So
Science

Chinese ‘yeast factory’ boosts cancer drug production by 1,000 times

Turning point comes from cross-disciplinary collaboration, including across plant biochemistry, synthetic biology and protein engineering.

videocam
China’s private sector

China’s drug firms set to compete on the world stage, analysts say

Amid systemic efficiency and a wave of innovation, the country’s biotech sector is expanding at a pace that has caught the market off guard.

4
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement